NI200700094A - METHODS FOR NEUROPROTECTION - Google Patents
METHODS FOR NEUROPROTECTIONInfo
- Publication number
- NI200700094A NI200700094A NI200700094A NI200700094A NI200700094A NI 200700094 A NI200700094 A NI 200700094A NI 200700094 A NI200700094 A NI 200700094A NI 200700094 A NI200700094 A NI 200700094A NI 200700094 A NI200700094 A NI 200700094A
- Authority
- NI
- Nicaragua
- Prior art keywords
- formula
- group
- phenyl
- alkyl
- methods
- Prior art date
Links
- 230000004112 neuroprotection Effects 0.000 title abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 3
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 abstract 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 abstract 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 abstract 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 abstract 1
- 229910052794 bromium Inorganic materials 0.000 abstract 1
- 229910052801 chlorine Inorganic materials 0.000 abstract 1
- 239000000460 chlorine Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 229910052731 fluorine Inorganic materials 0.000 abstract 1
- 239000011737 fluorine Substances 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 150000002367 halogens Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 229910052740 iodine Inorganic materials 0.000 abstract 1
- 239000011630 iodine Substances 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Virology (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
Abstract
Ésta invención está dirigida a métodos para proveer neuroprotección que comprende la administración a un sujeto en necesidad de los mismos una cantidad terapéuticamente efectiva de un compuesto seleccionado del grupo que compone la Fórmula (I) y Fórmula (II), o una sal o éster farmacéuticamente aceptable de los mismos,: Fórmula (I), Fórmula (II) en donde el fenilo es sustituido en X con de uno a cinco átomos de halógeno seleccionados del grupo que consiste en flúor, cloro, bromo y yodo; y, R1, R2, R3, R4, R5 y R6 son seleccionados independientemente del grupo que consiste en hidrógeno y alquilo C1-C4; en donde el alquilo C1-C4 es sustituido opcionalmente con fenilo ( en donde el fenilo es sustituido opcionalmente con sustituyentes seleccionados independientemente del grupo que consiste en halógeno, alquilo C1-C4, alcoxi C1-C4, amino, nitro y ciano).This invention is directed to methods for providing neuroprotection comprising administration to a subject in need thereof a therapeutically effective amount of a compound selected from the group that makes up Formula (I) and Formula (II), or a pharmaceutically acceptable salt or ester acceptable thereof: Formula (I), Formula (II) wherein the phenyl is substituted in X with one to five halogen atoms selected from the group consisting of fluorine, chlorine, bromine and iodine; and, R1, R2, R3, R4, R5 and R6 are independently selected from the group consisting of hydrogen and C1-C4 alkyl; wherein the C1-C4 alkyl is optionally substituted with phenyl (wherein the phenyl is optionally substituted with substituents independently selected from the group consisting of halogen, C1-C4 alkyl, C1-C4 alkoxy, amino, nitro and cyano).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US61940204P | 2004-10-15 | 2004-10-15 | |
| US69840305P | 2005-07-12 | 2005-07-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NI200700094A true NI200700094A (en) | 2008-02-11 |
Family
ID=35840528
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NI200700094A NI200700094A (en) | 2004-10-15 | 2005-10-14 | METHODS FOR NEUROPROTECTION |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP1802294A1 (en) |
| JP (1) | JP2008516961A (en) |
| KR (3) | KR20090130175A (en) |
| AU (1) | AU2005295787A1 (en) |
| BR (1) | BRPI0516112A (en) |
| CA (1) | CA2584854A1 (en) |
| EA (1) | EA200700871A1 (en) |
| EC (1) | ECSP077395A (en) |
| IL (1) | IL182432A0 (en) |
| MX (1) | MX2007004491A (en) |
| NI (1) | NI200700094A (en) |
| NO (1) | NO20072444L (en) |
| SG (1) | SG142306A1 (en) |
| WO (1) | WO2006044472A1 (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2783699C (en) | 2009-12-08 | 2019-01-15 | Case Western Reserve University | Primary amine compounds for treating ocular disorders |
| US8609849B1 (en) | 2010-11-30 | 2013-12-17 | Fox Chase Chemical Diversity Center, Inc. | Hydroxylated sulfamides exhibiting neuroprotective action and their method of use |
| US8652527B1 (en) | 2013-03-13 | 2014-02-18 | Upsher-Smith Laboratories, Inc | Extended-release topiramate capsules |
| US9101545B2 (en) | 2013-03-15 | 2015-08-11 | Upsher-Smith Laboratories, Inc. | Extended-release topiramate capsules |
| KR20190081385A (en) | 2017-12-29 | 2019-07-09 | 강원대학교산학협력단 | Composition for preventing the ischemia stroke disease containing oxcarbazepine |
| FR3110393B1 (en) * | 2020-05-20 | 2022-05-06 | Grn Consulting | COMPOUND AND COMPOSITION FOR INDUCING NEUROPROTECTION |
| JP2023539291A (en) * | 2020-08-31 | 2023-09-13 | バイオ－ファーム ソリューションズ カンパニー リミテッド | Phenylalkyl carbamate compounds for the prevention or treatment of neurodegenerative diseases |
| KR20230051206A (en) | 2020-09-10 | 2023-04-17 | (주)바이오팜솔루션즈 | Sulfamate derivative compounds for the treatment or alleviation of mental disorders |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20010034365A1 (en) * | 1996-01-16 | 2001-10-25 | Choi Yong Moon | Halogen substituted carbamate compounds from 2-phenyl-1,2-ethanediol |
| US5698588A (en) * | 1996-01-16 | 1997-12-16 | Yukong Limited | Halogen substituted carbamate compounds from 2-phenyl-1,2-ethanediol |
| MXPA02001820A (en) * | 1999-08-20 | 2003-07-14 | Johnson & Johnson | Composition comprising a tramadol material and an anticonvulsant drug. |
| PT1383489E (en) * | 2001-02-27 | 2007-06-21 | Ortho Mcneil Pharm Inc | Carbamate compounds for use in preventing or treating neurodegenerative disorders |
| CA2580640A1 (en) * | 2004-09-16 | 2006-03-30 | Janssen Pharmaceutica N.V. | Methods of treating epileptogensis and epilepsy |
-
2005
- 2005-10-14 AU AU2005295787A patent/AU2005295787A1/en not_active Abandoned
- 2005-10-14 BR BRPI0516112-6A patent/BRPI0516112A/en not_active IP Right Cessation
- 2005-10-14 WO PCT/US2005/036695 patent/WO2006044472A1/en not_active Ceased
- 2005-10-14 KR KR1020097019737A patent/KR20090130175A/en not_active Ceased
- 2005-10-14 EP EP05810159A patent/EP1802294A1/en not_active Withdrawn
- 2005-10-14 JP JP2007536843A patent/JP2008516961A/en active Pending
- 2005-10-14 NI NI200700094A patent/NI200700094A/en unknown
- 2005-10-14 SG SG200802877-1A patent/SG142306A1/en unknown
- 2005-10-14 CA CA002584854A patent/CA2584854A1/en not_active Abandoned
- 2005-10-14 KR KR1020077010744A patent/KR20070085309A/en not_active Ceased
- 2005-10-14 EA EA200700871A patent/EA200700871A1/en unknown
- 2005-10-14 KR KR1020117007395A patent/KR20110049901A/en not_active Ceased
- 2005-10-14 MX MX2007004491A patent/MX2007004491A/en unknown
-
2007
- 2007-04-10 IL IL182432A patent/IL182432A0/en unknown
- 2007-04-13 EC EC2007007395A patent/ECSP077395A/en unknown
- 2007-05-11 NO NO20072444A patent/NO20072444L/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| KR20070085309A (en) | 2007-08-27 |
| CA2584854A1 (en) | 2006-04-27 |
| JP2008516961A (en) | 2008-05-22 |
| KR20110049901A (en) | 2011-05-12 |
| BRPI0516112A (en) | 2008-08-26 |
| EP1802294A1 (en) | 2007-07-04 |
| NO20072444L (en) | 2007-06-14 |
| AU2005295787A1 (en) | 2006-04-27 |
| SG142306A1 (en) | 2008-05-28 |
| ECSP077395A (en) | 2007-05-30 |
| WO2006044472A1 (en) | 2006-04-27 |
| IL182432A0 (en) | 2007-09-20 |
| MX2007004491A (en) | 2007-08-08 |
| KR20090130175A (en) | 2009-12-18 |
| EA200700871A1 (en) | 2007-10-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NI200800008A (en) | METHODS FOR NEUROPROTECTION | |
| ECSP088172A (en) | METHODS TO TREAT EPILEPTOGENESIS | |
| CO6180427A2 (en) | TREATMENT OF THE GENERALIZED DISORDERS OF DEVELOPMENT | |
| IL181910A0 (en) | Use of 2-phenyl-1,2-ethanediol-(di) carbamates for treating epileptogenesis and epilepsy | |
| CO5601006A2 (en) | PROCEDURE FOR THE PREPARATION OF ESCOPINE ESTERS | |
| AR063015A1 (en) | DERIVATIVES OF QUINAZOLINONA 5-SUBSTITUTE AND COMPOSITIONS THAT INCLUDE THEM AND METHODS TO USE THEM IN THE TREATMENT OF CANCER | |
| CL2012000999A1 (en) | Substituted pyrazolospiroketone derivative compounds, acetyl-coa carboxylase inhibitors; pharmaceutical composition comprising them; use to treat or delay the progression or onset of type 2 diabetes, non-alcoholic fatty liver (hgna), or hepatic insulin resistance. | |
| ECSP077395A (en) | CARBAMATE COMPOUND FOR USE IN THE TREATMENT OF NEURODEGENERATIVE PADCIMIENTS | |
| AR054524A1 (en) | METHODS AND DOSAGE FORMS TO REDUCE THE SIDE EFFECTS OF CARBAMATE COMPOUNDS | |
| AR064241A1 (en) | METHODS FOR THE TREATMENT OF DEPRESSION | |
| CO6180505A2 (en) | METHODS FOR THE TREATMENT OF COCLEAR AND VESTIBULAR DISORDERS | |
| IL157590A0 (en) | Carbamate compounds for use in preventing or treating bipolar disorder | |
| EA200701536A1 (en) | WAYS OF QT INTERVAL CONTROL | |
| AR033427A1 (en) | USE OF CARBAMATE COMPOUNDS IN PAIN TREATMENT | |
| CO6160292A2 (en) | METHODS OF TREATMENT OF DISTURBING BEHAVIOR DISORDERS 877 | |
| EA200800422A1 (en) | METHODS OF TREATMENT OF DISEASES DETERMINED BY CHEMICALS | |
| AR077884A1 (en) | (4- (5-AMINOMETIL- PHENYL) -PIPERIDIN-1-IL) -1H-INDOL-3-IL) -DISTITUTED METHONES | |
| SE0401578D0 (en) | Novel compounds | |
| AR035757A1 (en) | USE OF CARBAMATES FOR THE MANUFACTURE OF MEDICINES TO PREVENT OR TREAT A BIPOLAR DISORDER | |
| UY29158A1 (en) | METHODS OF TREATMENT OF EPILEPTOGENESIS AND EPILEPSY | |
| PE20060559A1 (en) | CARBAMATE-DERIVED COMPOUNDS FOR THE TREATMENT OF SUBSTANCE-RELATED DISORDERS | |
| MY136733A (en) | Carbamate compounds for use in preventing or treating psychotic disorders | |
| CY1110672T1 (en) | USE OF 2- FENYL-1,2-ETHANODIOL- (DI) CARBAMIC FOR SELECTION THERAPY | |
| AR032907A1 (en) | USE OF CARBAMATE COMPOUNDS FOR THE PREVENTION OR TREATMENT OF ANXIETY DISORDERS |